Point of Care Molecular Diagnostics Device Market – Global Industry Analysis and Forecast (2022 – 2029)


Point of Care Molecular Diagnostics Device Market is expected to grow at a CAGR of 14.7% during the forecast period and market is expected to reach US$ 3.47 Bn. by 2029.

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.

Global Point of Care Molecular Diagnostics Device Market

To know about the Research Methodology :- Request Free Sample Report

Some of the key market drivers include the increasing technological advancements, ability to diagnose infectious diseases at sites with a limited infrastructure, availability of clinical evidence for the safety and efficacy procedures, patients awareness about better healthcare options and readiness for rising healthcare expenditures, changing technology and innovation, changing demographics and lifestyles leading to an increased prevalence of peripheral vascular diseases, adoption of new products, rising demand for advanced medical instruments, geriatric population.

Point of Care Molecular Diagnostics Device Market is segmented by product & service, technology, application, end user, and region. Point of Care Molecular Diagnostics Device Market has the largest usage in Physician Offices, Hospital Emergency Departments & Intensive Care Units, and Research Institutes

Geographically, global point of care molecular diagnostics device market is classified into North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW). In 2018, North America is anticipated to have the largest share in the global adhesion barrier market. The largest ratio of the North American market can mostly be attributed to the high prevalence of technologically advanced medical framework, sophisticated insurance & co-payment system & high R&D investment by governments and private funding organizations for the development of POC MDx tests are major factors responsible for the region’s dominant market position. Availability of clinical evidence for the safety and efficacy of point of care molecular diagnostics procedures, transmuting technology and innovation.

Asia Pacific market is expected to grow at the fastest rate during the forecast period owing to the increasing demand for POC test. Many minuscule players are looking forward to investment in the Asia Pacific market due to sizable patient pool and incremental utilization of global adhesion barrier market devices.

The key players in the Point of Care Molecular Diagnostics Device Market include Roche Diagnostics (Switzerland), Biomerieux (France), Danaher (US), Abbott Laboratories (US), Quidel (US) and Meridian Bioscience (US).

Point of Care Molecular Diagnostics Device Market Target Audience:

• POC Molecular Diagnostics Manufacturers
• Physicians
• Research Institutes
• Diagnostics Suppliers
• Market Research and Consulting Firms
• Regulatory Bodies
• Venture Capitalists

Point of Care Molecular Diagnostics Device Market Scope: Inquire before buying


• Point of Care Molecular Diagnostics Device Market, By Product & Service:

o Assays & Kits
o Instruments/Analysers
o Services & Software

•Point of Care Molecular Diagnostics Device Market,  By Application:

o Respiratory diseases
o STDs
o HAIs
o Oncology
o Hepatitis

•Point of Care Molecular Diagnostics Device Market,  By Technology:

o RT-PCR
o INAAT
o Others Technologies

• Point of Care Molecular Diagnostics Device Market, By End User:

o Physician Offices
o Hospital Emergency Departments & Intensive Care Units
o Research Institutes
o Other End User

Point of Care Molecular Diagnostics Device Market, by Region

North America
• U.S
• Canada

Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• Rest of Asia Pacific

Rest of the World (ROW):
• Middle-East
• Africa
• Latin America

Point of Care Molecular Diagnostics Device Market Key Players :

• Abacus Diagnostica
• Advanced Liquid Logic (Illumina)
• Ahram Biosystems
• Akonni Biosystems
• Alere (Abbott)
• Amplino
• Analytik Jena
• Aquila Diagnostic Systems
• Atlas Genetics
• Axxin
• Becton, Dickinson & Co. (BD)
• Biocartis
• Biomeme
• bioMérieux
• Canon BioMedical
• Cepheid
• Coris BioConcept
• Coyote Bioscience
• Curetis
• DestiNA Genomics
• Diagnostics For All
• Diagnostics for the Real World
• DiaSorin
• DiAssess
• DNA Electronics
• DxNA

Frequently Asked Questions:

1. Which region has the largest share in Global Point of Care Molecular Diagnostics Device Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Global Point of Care Molecular Diagnostics Device Market?
Ans: The Global Point of Care Molecular Diagnostics Device Market is growing at a CAGR of 14.7% during forecasting period 2022-2029.

3. What is scope of the Global Point of Care Molecular Diagnostics Device market report?
Ans: Global Point of Care Molecular Diagnostics Device Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Point of Care Molecular Diagnostics Device market?
Ans: The important key players in the Global Point of Care Molecular Diagnostics Device Market are – Abacus Diagnostica, Advanced Liquid Logic (Illumina), Ahram Biosystems, Akonni Biosystems, Alere (Abbott), Amplino, Analytik Jena, Aquila Diagnostic Systems, Atlas Genetics, Axxin, Becton, Dickinson & Co. (BD), Biocartis, Biomeme, bioMérieux, Canon BioMedical, Cepheid, Coris BioConcept, Coyote Bioscience, Curetis, DestiNA Genomics, Diagnostics For All, Diagnostics for the Real World, DiaSorin, DiAssess, DNA Electronics, and DxNA.

5. What is the study period of this market?
Ans: The Global Point of Care Molecular Diagnostics Device Market is studied from 2021 to 2029. 





Point of Care Molecular Diagnostics Device Market

1. INTRODUCTION
1.1. Market description & Scope (2021-2029)
1.2. Objectives
1.2.1. Key Takeaways
1.2.2. Abbreviations & Acronyms
2. RESEARCH METHODOLOGY
2.1. Methods used for market forecasting
2.2. Data
2.2.1. Paid
2.2.2. Primary
2.2.3. Secondary
3. EXECUTIVE SUMMARY
3.1. Major Findings
3.1.1. Key Segment Trends
3.1.1.1. Product & Service
3.1.1.2. Application
3.1.1.3. Technology
3.1.1.4. End User
3.1.2. Key Regional Trends
3.1.2.1. North America
3.1.2.2. Europe
3.1.2.3. Asia Pacific
3.1.2.4. Rest of the World
3.2. Key Companies and their Strategies
4. MARKET OVERVIEW
4.1. Point of Care Molecular Diagnostics Concept & Definition
4.2. Segments Overview
4.2.1. By product & Service
4.2.1.1.1.1. Assays & Kits
4.2.1.1.1.2. Instruments/Analysers
4.2.1.1.1.3. Services & Software
4.2.2. By Application
4.2.2.1.1. Respiratory diseases
4.2.2.1.2. STDs
4.2.2.1.3. HAIs
4.2.2.1.4. Oncology
4.2.2.1.5. Hepatitis
4.2.2.2. By Technology
4.2.2.2.1. RT-PCR
4.2.2.2.2. INAAT
4.2.2.2.3. Others Technologies
4.2.2.3. By End User
4.2.2.3.1. Physician Offices
4.2.2.3.2. Hospital Emergency Departments & Intensive Care Units
4.2.2.3.3. Research Institutes
4.2.2.3.4. Other End User
4.2.3. Market Dynamics
4.2.3.1. Drivers
4.2.3.2. Restraints
4.2.3.3. Opportunities
4.3. Porter’s Analysis
4.4. PESTLE Analysis
4.5. Fragmentation
4.5.1. Key strategic Alliances of companies (inorganic & organic)
4.5.2. Company Market Share (Top 10 Players)
4.5.3. Comparative Analysis of Key players in Recycled Plastics
4.6. Key Trends
4.7. Key Trends in Global Point of Care Molecular Diagnostics Device Market
5. POINT OF CARE MOLECULAR DIAGNOSTICS PRODUCT & SERVICE TREND ANALYSIS (2021-2029)
5.1. Point of Care Molecular Diagnostics Market Product & Service Analysis
5.1.1. Assays & Kits
5.1.1.1. Market Share and growth forecasts, 2021-2029(USD Billion)
5.1.2. Instruments/Analysers
5.1.2.1. Market Share and growth forecasts, 2021-2029(USD Billion)
5.1.3. Services & Software
5.1.3.1. Market Share and growth forecasts, 2021-2029(USD Billion)
5.2. Point of Care Molecular Diagnostics Market: Product Trends
6. POINT OF CARE MOLECULAR DIAGNOSTICS APPLICATION ESTIMATES & TREND ANALYSIS (2021-2029)
6.1. Point of Care Molecular Diagnostics Application Market Analysis
6.1.1. Respiratory diseases
6.1.1.1. Market Share and growth forecasts, 2021-2029(USD Billion)
6.1.2. STDs
6.1.2.1. Market Share and growth forecasts, 2021-2029(USD Billion)
6.1.3. HAIs
6.1.3.1. Market Share and growth forecasts, 2021-2029(USD Billion)
6.1.4. Oncology
6.1.4.1. Market Share and growth forecasts, 2021-2029(USD Billion)
6.1.5. Hepatitis
6.1.5.1. Market Share and growth forecasts, 2021-2029(USD Billion)
6.2. Point of Care Molecular Diagnostics Market: Application Trends
7. POINT OF CARE MOLECULAR DIAGNOSTICS TECHNOLOGY ESTIMATES & TREND ANALYSIS (2021-2029)
7.1. Point of Care Molecular Diagnostics Application Market Analysis
7.1.1. RT-PCR
7.1.1.1. Market Share and growth forecasts, 2021-2029(USD Billion)
7.1.2. INAAT
7.1.2.1. Market Share and growth forecasts, 2021-2029(USD Billion)
7.1.3. Others Technologies
7.1.3.1. Market Share and growth forecasts, 2021-2029(USD Billion)
7.2. Point of Care Molecular Diagnostics Market: Application Trends
8. POINT OF CARE MOLECULAR DIAGNOSTICS END USE ESTIMATES & TREND ANALYSIS (2021-2029)
8.1. Point of Care Molecular Diagnostics End Use Market Analysis
8.1.1. Physician Offices
8.1.1.1. Market Share and growth forecasts, 2021-2029(USD Billion)
8.1.2. Hospital Emergency Departments & Intensive Care Units
8.1.2.1. Market Share and growth forecasts, 2021-2029(USD Billion)
8.1.3. Research Institutes
8.1.3.1. Market Share and growth forecasts, 2021-2029(USD Billion)
8.1.4. Other End User
8.1.4.1. Market Share and growth forecasts, 2021-2029(USD Billion)
8.2. Point of Care Molecular Diagnostics Market: End-user Trends
9. REGIONAL ESTIMATES & TREND ANALYSIS (2021-2029)
9.1. Point of Care Molecular Diagnostics Market share by Region, 2021 & 2029
9.2. North America
9.2.1. North America Point of Care Molecular Diagnostics market, Market Share and growth forecasts, 2021-2029(USD Billion)
9.2.2. Point of Care Molecular Diagnostics Drivers For North America Market
9.2.3. Market Share Analysis and Growth Forecast, by Country
9.2.3.1. US
9.2.3.2. Canada
9.2.4. Country-wise GDP Growth Forecast
9.2.5. Point of Care Molecular Diagnostics Trends In North America Market
9.3. Europe
9.3.1. Europe Point of Care Molecular Diagnostics market, Market Share and growth forecasts, 2021-2029(USD Billion)
9.3.2. Point of Care Molecular Diagnostics Drivers For Europe Market
9.3.3. Market Share Analysis and Growth Forecast, by Country
9.3.3.1. UK
9.3.3.2. Germany
9.3.3.3. France
9.3.3.4. Russia
9.3.3.5. Spain
9.3.3.6. Italy
9.3.3.7. Others
9.3.4. Country-wise GDP Growth Forecast
9.3.5. Point of Care Molecular Diagnostics Trends In Europe Market
9.4. Asia Pacific
9.4.1. Asia Pacific Point of Care Molecular Diagnostics market, Market Share and growth forecasts, 2021-2029(USD Billion)
9.4.2. Point of Care Molecular Diagnostics Drivers For Asia Pacific Market
9.4.3. Market Share Analysis and Growth Forecast, by Country
9.4.3.1. China
9.4.3.2. Japan
9.4.3.3. India
9.4.3.4. South Korea
9.4.3.5. Australia
9.4.3.6. Others
9.4.4. Country-wise GDP Growth Forecast
9.4.5. Point of Care Molecular Diagnostics Trends In Asia Pacific Market
9.5. Rest of the World
9.5.1. Rest of the World Point of Care Molecular Diagnostics Market, Market Share and growth forecasts, 2021-2029(USD Billion)
9.5.2. Point of Care Molecular Diagnostics Drivers For Rest of the World Market
9.5.3. Market Share Analysis and Growth Forecast, by Country
9.5.3.1. Middle-East
9.5.3.2. Africa
9.5.3.3. Latin America
9.5.4. Country-wise GDP Growth Forecast
9.5.5. Point of Care Molecular Diagnostics Trends In Rest of the World Market
10. MARKET SHARE ANALYSIS
10.1. Key Players Regional Market share Analysis
10.1.1. North America
10.1.2. Europe
10.1.3. Asia Pacific
10.1.4. Middle-east
10.1.5. Latin America
11. MARKET COMPETITION ANALYSIS
11.1. Strategy Framework
11.2. Consolidation
11.2.1. Patent Analysis
11.2.2. Mergers & Acquisitions
11.2.2.1. Product Based
11.2.2.2. Services Based
11.2.2.3. Region Based
11.2.2.4. List of Mergers & Acquisitions
11.2.3. Company Benchmarking (Revenue & Profit Based)
11.2.4. Strategic Assessment of Company Consolidations
11.2.5. Emerging Business Models
11.3. Company Profiles
11.3.1. Abacus Diagnostica
11.3.1.1. Company overview
11.3.1.2. Key financials
11.3.1.3. Geographical presence
11.3.1.4. Product and Business Segments
11.3.1.5. Strategic initiatives
11.3.1.6. SWOT analysis
11.3.1.7. Competitive positioning and landscape
11.3.2. Advanced Liquid Logic (Illumina)
11.3.2.1. Company overview
11.3.2.2. Key financials
11.3.2.3. Geographical presence
11.3.2.4. Product and Business Segments
11.3.2.5. Strategic initiatives
11.3.2.6. SWOT analysis
11.3.2.7. Competitive positioning and landscape
11.3.3. Ahram Biosystems
11.3.3.1. Company overview
11.3.3.2. Key financials
11.3.3.3. Geographical presence
11.3.3.4. Product and Business Segments
11.3.3.5. Strategic initiatives
11.3.3.6. SWOT analysis
11.3.3.7. Competitive positioning and landscape
11.3.4. Akonni Biosystems
11.3.4.1. Company overview
11.3.4.2. Key financials
11.3.4.3. Geographical presence
11.3.4.4. Product and Business Segments
11.3.4.5. Strategic initiatives
11.3.4.6. SWOT analysis
11.3.4.7. Competitive positioning and landscape
11.3.5. Alere (Abbott)
11.3.5.1. Company overview
11.3.5.2. Key financials
11.3.5.3. Geographical presence
11.3.5.4. Product and Business Segments
11.3.5.5. Strategic initiatives
11.3.5.6. SWOT analysis
11.3.5.7. Competitive positioning and landscape
11.3.6. Amplino
11.3.6.1. Company overview
11.3.6.2. Key financials
11.3.6.3. Geographical presence
11.3.6.4. Product and Business Segments
11.3.6.5. Strategic initiatives
11.3.6.6. SWOT analysis
11.3.6.7. Competitive positioning and landscape
11.3.7. Analytik Jena
11.3.7.1. Company overview
11.3.7.2. Key financials
11.3.7.3. Geographical presence
11.3.7.4. Product and Business Segments
11.3.7.5. Strategic initiatives
11.3.7.6. SWOT analysis
11.3.7.7. Competitive positioning and landscape
11.3.8. Aquila Diagnostic Systems
11.3.8.1. Company overview
11.3.8.2. Key financials
11.3.8.3. Geographical presence
11.3.8.4. Product and Business Segments
11.3.8.5. Strategic initiatives
11.3.8.6. SWOT analysis
11.3.8.7. Competitive positioning and landscape
11.3.9. Atlas Genetics
11.3.9.1. Company overview
11.3.9.2. Key financials
11.3.9.3. Geographical presence
11.3.9.4. Product and Business Segments
11.3.9.5. Strategic initiatives
11.3.9.6. SWOT analysis
11.3.9.7. Competitive positioning and landscape
11.3.10. Axxin
11.3.10.1. Company overview
11.3.10.2. Key financials
11.3.10.3. Geographical presence
11.3.10.4. Product and Business Segments
11.3.10.5. Strategic initiatives
11.3.10.6. SWOT analysis
11.3.10.7. Competitive positioning and landscape
11.3.11. Becton, Dickinson & Co. (BD)
11.3.11.1. Company overview
11.3.11.2. Key financials
11.3.11.3. Geographical presence
11.3.11.4. Product and Business Segments
11.3.11.5. Strategic initiatives
11.3.11.6. SWOT analysis
11.3.11.7. Competitive positioning and landscape
11.3.12. Biocartis
11.3.12.1. Company overview
11.3.12.2. Key financials
11.3.12.3. Geographical presence
11.3.12.4. Product and Business Segments
11.3.12.5. Strategic initiatives
11.3.12.6. SWOT analysis
11.3.12.7. Competitive positioning and landscape
11.3.13. Biomeme
11.3.13.1. Company overview
11.3.13.2. Key financials
11.3.13.3. Geographical presence
11.3.13.4. Product and Business Segments
11.3.13.5. Strategic initiatives
11.3.13.6. SWOT analysis
11.3.13.7. Competitive positioning and landscape
11.3.14. bioMérieux
11.3.14.1. Company overview
11.3.14.2. Key financials
11.3.14.3. Geographical presence
11.3.14.4. Product and Business Segments
11.3.14.5. Strategic initiatives
11.3.14.6. SWOT analysis
11.3.14.7. Competitive positioning and landscape
11.3.15. Canon BioMedical
11.3.15.1. Company overview
11.3.15.2. Key financials
11.3.15.3. Geographical presence
11.3.15.4. Product and Business Segments
11.3.15.5. Strategic initiatives
11.3.15.6. SWOT analysis
11.3.15.7. Competitive positioning and landscape
11.3.16. Cepheid
11.3.16.1. Company overview
11.3.16.2. Key financials
11.3.16.3. Geographical presence
11.3.16.4. Product and Business Segments
11.3.16.5. Strategic initiatives
11.3.16.6. SWOT analysis
11.3.16.7. Competitive positioning and landscape
11.3.17. Coris BioConcept
11.3.17.1. Company overview
11.3.17.2. Key financials
11.3.17.3. Geographical presence
11.3.17.4. Product and Business Segments
11.3.17.5. Strategic initiatives
11.3.17.6. SWOT analysis
11.3.17.7. Competitive positioning and landscape
11.3.18. Coyote Bioscience
11.3.18.1. Company overview
11.3.18.2. Key financials
11.3.18.3. Geographical presence
11.3.18.4. Product and Business Segments
11.3.18.5. Strategic initiatives
11.3.18.6. SWOT analysis
11.3.18.7. Competitive positioning and landscape
11.3.19. Curetis
11.3.19.1. Company overview
11.3.19.2. Key financials
11.3.19.3. Geographical presence
11.3.19.4. Product and Business Segments
11.3.19.5. Strategic initiatives
11.3.19.6. SWOT analysis
11.3.19.7. Competitive positioning and landscape
11.3.20. DestiNA Genomics
11.3.20.1. Company overview
11.3.20.2. Key financials
11.3.20.3. Geographical presence
11.3.20.4. Product and Business Segments
11.3.20.5. Strategic initiatives
11.3.20.6. SWOT analysis
11.3.20.7. Competitive positioning and landscape
11.3.21. Diagnostics For All
11.3.21.1. Company overview
11.3.21.2. Key financials
11.3.21.3. Geographical presence
11.3.21.4. Product and Business Segments
11.3.21.5. Strategic initiatives
11.3.21.6. SWOT analysis
11.3.21.7. Competitive positioning and landscape
11.3.22. Diagnostics for the Real World
11.3.22.1. Company overview
11.3.22.2. Key financials
11.3.22.3. Geographical presence
11.3.22.4. Product and Business Segments
11.3.22.5. Strategic initiatives
11.3.22.6. SWOT analysis
11.3.22.7. Competitive positioning and landscape
11.3.23. DiaSorin
11.3.23.1. Company overview
11.3.23.2. Key financials
11.3.23.3. Geographical presence
11.3.23.4. Product and Business Segments
11.3.23.5. Strategic initiatives
11.3.23.6. SWOT analysis
11.3.23.7. Competitive positioning and landscape
11.3.24. DiAssess
11.3.24.1. Company overview
11.3.24.2. Key financials
11.3.24.3. Geographical presence
11.3.24.4. Product and Business Segments
11.3.24.5. Strategic initiatives
11.3.24.6. SWOT analysis
11.3.24.7. Competitive positioning and landscape
11.3.25. DNA Electronics
11.3.25.1. Company overview
11.3.25.2. Key financials
11.3.25.3. Geographical presence
11.3.25.4. Product and Business Segments
11.3.25.5. Strategic initiatives
11.3.25.6. SWOT analysis
11.3.25.7. Competitive positioning and landscape
11.3.26. DxNA
11.3.26.1. Company overview
11.3.26.2. Key financials
11.3.26.3. Geographical presence
11.3.26.4. Product and Business Segments
11.3.26.5. Strategic initiatives
11.3.26.6. SWOT analysis
11.3.26.7. Competitive positioning and landscape
  • INQUIRE BEFORE BUYING